Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of “Moderate Buy” from Brokerages

by · The Cerbat Gem

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twelve analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $19.8750.

A number of research analysts recently commented on JSPR shares. JMP Securities lowered their price target on shares of Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating for the company in a report on Monday, September 22nd. BTIG Research lowered their price objective on Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, September 22nd. Rodman & Renshaw initiated coverage on Jasper Therapeutics in a research report on Tuesday, January 13th. They set a “buy” rating and a $17.00 target price on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Wednesday, October 8th. Finally, Evercore ISI dropped their price objective on shares of Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating for the company in a research note on Monday, September 22nd.

View Our Latest Stock Report on JSPR

Jasper Therapeutics Price Performance

Shares of NASDAQ JSPR traded up $0.01 during midday trading on Friday, reaching $1.53. 297,251 shares of the stock traded hands, compared to its average volume of 1,016,634. The company’s 50 day moving average is $1.75 and its 200 day moving average is $2.45. Jasper Therapeutics has a one year low of $1.39 and a one year high of $7.19. The stock has a market capitalization of $42.81 million, a PE ratio of -0.26 and a beta of 3.07.

Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.12). As a group, equities analysts forecast that Jasper Therapeutics will post -4.47 EPS for the current year.

Institutional Trading of Jasper Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. boosted its position in shares of Jasper Therapeutics by 11.2% during the first quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock valued at $1,005,000 after buying an additional 23,453 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Jasper Therapeutics during the 1st quarter worth approximately $46,000. Bank of Montreal Can boosted its holdings in Jasper Therapeutics by 120.4% during the 2nd quarter. Bank of Montreal Can now owns 158,133 shares of the company’s stock valued at $878,000 after acquiring an additional 86,393 shares during the period. JPMorgan Chase & Co. grew its position in Jasper Therapeutics by 1,074.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 65,088 shares of the company’s stock valued at $361,000 after acquiring an additional 59,547 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Jasper Therapeutics in the second quarter worth $152,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

About Jasper Therapeutics

(Get Free Report)

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.

Recommended Stories